The share buy-back program will start on March 26, 2025, and is expected to end no later than July 10, 2025 (unless Genmab terminates or suspends the program).
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. Genmab A/S has moved -37.4% over the last year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback